Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Toggle navigation
Contact Us
Subscribe
Promote Your Event
e-Edition
Privacy Policy
Terms of Service
Local Weather
Home Delivery
Submission Forms
News
Local News
The Leader
Heartland News
Sports
Entertainment
Local Events
Multimedia
Photo Galleries
Videos
Obituaries
Classifieds
Real Estate
Property for Rent
Cars & Vehicles
Jobs
Items for Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Legals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Exelixis, Inc.
< Previous
1
2
3
Next >
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
November 21, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
November 10, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 01, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
October 22, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
October 18, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
September 12, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
August 24, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
August 23, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
August 21, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 01, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
July 23, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
July 18, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
May 30, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
May 07, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
May 03, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
May 01, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
April 25, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Advances Board Refreshment Plan
April 13, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Reiterates Commitment to Shareholder Value Creation
April 05, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces $550 Million Share Repurchase Program
March 20, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
March 13, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
March 02, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
February 28, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
February 13, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 07, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
February 02, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
January 24, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Update on Patent Litigation with MSN Laboratories
January 19, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
January 08, 2023
From
Exelixis, Inc.
Via
Business Wire
Tickers
EXEL
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.